C8orf31 Inhibitors
C8orf31 inhibitors are compounds that can reduce the functional activity of the protein C8orf31. These inhibitors operate on the principle of targeting certain biochemical or cellular pathways that C8orf31 is directly involved in. For instance, BAPTA-AM, which is a calcium chelator, functions by disrupting calcium-dependent signaling cascades that may involve C8orf31. Similarly, KN-62, an inhibitor of calcium/calmodulin-dependent protein kinase II (CaMKII), can decrease the activity of C8orf31 if it is involved in CaMKII signaling.
Other inhibitors, like PP2, inhibit Src-family tyrosine kinases, and can reduce C8orf31's functional activity if it's a downstream effector in Src-related pathways. Genistein, a broad-spectrum tyrosine kinase inhibitor, can also decrease C8orf31 activity if its function is regulated by tyrosine phosphorylation. Inhibition of calmodulin, a protein known to interact with several target proteins, by Calmidazolium chloride and W-7 hydrochloride can also lead to reduced activity of C8orf31 if its function is modulated by calmodulin-mediated signaling. Similarly, if C8orf31 is involved in PI3K/Akt signaling, PI3K inhibitors like LY294002 can reduce its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM is a cell-permeable calcium chelator. By reducing intracellular calcium levels, it can disrupt calcium-dependent signaling cascades that may involve C8orf31. | ||||||
KN-62 | 127191-97-3 | sc-3560 | 1 mg | $136.00 | 20 | |
KN-62 is an inhibitor of calcium/calmodulin-dependent protein kinase II (CaMKII). If C8orf31 is involved in CaMKII signaling, its activity can be decreased by this compound. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a potent inhibitor of Src-family tyrosine kinases. If C8orf31 is a downstream effector in Src-related pathways, its functional activity could be reduced by PP2. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is an FGFR1 inhibitor. If C8orf31 is involved in FGFR1 signaling, its activity could be decreased by PD173074. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a broad-spectrum tyrosine kinase inhibitor. If C8orf31's function is regulated by tyrosine phosphorylation, Genistein could reduce its activity. | ||||||
Calmidazolium chloride | 57265-65-3 | sc-201494 sc-201494A | 10 mg 50 mg | $156.00 $612.00 | 27 | |
Calmidazolium chloride is a calmodulin inhibitor. If C8orf31's function is modulated by calmodulin-mediated signaling, this compound could inhibit its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor which blocks PI3K/Akt signaling. If C8orf31 functions downstream of this pathway, inhibition of Akt would reduce C8orf31 activity. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö 6983 is a broad-spectrum PKC inhibitor. If C8orf31 is involved in PKC signaling, its activity could be reduced by Gö 6983. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
W-7 hydrochloride is a calmodulin antagonist. If C8orf31's function is regulated by calmodulin, this compound could inhibit its activity. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro-31-8220 is a potent PKC inhibitor. If C8orf31 is involved in PKC signaling, its activity could be reduced by Ro-31-8220. | ||||||